2026
Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a multicenter, randomized, double-blind, placebo-controlled study
Sergey N. Avdeev · Expert Review of Respiratory Medicine
Niche authoredRespiratoryInfectious Disease & HIV
Peer-reviewed output
Three decades of clinical science, published in the open.
Niche has designed, run and reported studies across cardiovascular medicine, respiratory disease, infection, metabolic health and clinical pharmacology. Every paper below is part of that record.
- 202
- Publications
- 124
- Journals
- 1992 to 2026
- Years covered
- 77
- Niche authored
Publications by year
19922026
Year range
to
Showing 202 of 202 publications
2026
Why do healthy volunteers participate in clinical trials?
Thijs van Iersel · British Journal of Clinical Pharmacology
Niche authoredClinical Pharmacology & PK
2025
Efficacy of Bovhyaluronidase Azoximer (Longidaza®) in Patients With Long-term Pulmonary Sequelae of COVID-19: A Randomized, Double-blind, Placebo-controlled Trial
S.N. Avdeev · American Journal of Respiratory and Critical Care Medicine
Niche authoredRespiratoryInfectious Disease & HIV
2025
Long-term frailty and physical performance transitions in older people with type-2 diabetes. The MIDFRAIL randomized clinical study
Olga Laosa · The Journal of Nutrition, Health & Aging
Niche authoredDiabetes & MetabolicAgeing & Frailty
2025
Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma
Matthew Chad Eastwood · ERJ Open Research
Niche authoredCardiovascular & HypertensionRespiratoryRenal & Urology
2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex
Matthew C. Eastwood · Journal of Allergy and Clinical Immunology: In Practice
Niche authoredRespiratoryImmunology & Allergy
2023
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
P. C. Taylor · BMC Medicine
Musculoskeletal & Pain
2023
Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges
Charles Mundy · Frontiers in Pharmacology
Niche authoredClinical Pharmacology & PK
2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control
Xue Zeng · The Journal of Allergy and Clinical Immunology
Niche authoredRespiratoryImmunology & Allergy
2023
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
G. Ariceta · Pediatric Nephrology
Other
2023
Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial
H. M. Reid · Frontiers in Pharmacology
Cardiovascular & HypertensionClinical Pharmacology & PK
2023
Multidisciplinary paper on patient blood management in cardiothoracic surgery in the UK: perspectives on practice during COVID-19
N. Al-Attar · Journal of Cardiothoracic Surgery
Cardiovascular & HypertensionInfectious Disease & HIV
2023
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
J. Barratt · Kidney International
Renal & UrologyImmunology & Allergy
2023
The future of clinical trials and drug development: 2050
Timothy C. Hardman · Drugs in Context
Niche authoredOther
2023
Urinary eicosanoids - novel biomarkers in T2-low severe asthma (ERS)
— · (Conference abstract)
RespiratoryRenal & Urology
2022
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine
Ronald Kompier · F1000Research
Niche authoredInfectious Disease & HIVImmunology & Allergy
2022
Aromatic ointments for the common cold: what does the science say?
A. Smith · Drugs in Context
Other
2022
Changes to working practices in medical communications during the COVID-19 pandemic: Insights from two surveys
Timothy C. Hardman · Medical Writing
Niche authoredInfectious Disease & HIV
2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes
P. Jane McDowell · American Journal of Respiratory and Critical Care Medicine
Niche authoredRespiratory
2022
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
John Busby · European Respiratory Journal
Niche authoredRespiratoryTrial Methodology & Evidence
2022
Impact of the COVID-19 Pandemic on Clinical Trial Conduct: Lessons for the Future
F. Harrison · f1000Research
Niche authoredInfectious Disease & HIV
2022
Lipidome Analysis in Brain and Peripheral Plasma Following Milk Fat Globule Membrane Supplementation in Rodents
R. Davies · Molecular Nutrition & Food Research
Cardiovascular & Hypertension
2022
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
S. V. Efimov · Drugs in Context
Niche authoredInfectious Disease & HIVImmunology & Allergy
2022
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation
S. Diver · Allergy
Niche authoredRespiratoryImmunology & Allergy
2021
A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts
David Gomez-Cabrero · GeroScience
Niche authoredAgeing & Frailty
2021
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease
Herbert Nar · ChemMedChem
Niche authoredInfectious Disease & HIV
2021
Azoximer Bromide: Mystery, Serendipity, and Promise
L. Y. Grivtsova · Frontiers in Oncology
Niche authoredOncology
2021
Challenges of working from home during the COVID-19 pandemic: A survey to inform working practices
Timothy C. Hardman · Medical Writing
Niche authoredInfectious Disease & HIV
2021
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Liam G. Heaney · The Lancet Respiratory Medicine
Niche authoredRespiratory
2021
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study
B. Hoppe · Nephrology Dialysis Transplantation
Renal & Urology
2021
How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum
J. Rengelshausen · Therapeutic Innovation & Regulatory Science
Niche authoredOther
2021
Human challenge trials the covid-19 vaccines still have much to teach us Response
J. Cheriyan · BMJ Opinion
Niche authoredInfectious Disease & HIV
2021
Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function—data from three placebo-controlled studies
D. S. Milliner · Pediatric Nephrology
Renal & Urology
2021
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
P. D. Monk · The Lancet Respiratory Medicine
RespiratoryInfectious Disease & HIV
2021
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
S. V. Efimov · Drugs in Context
Niche authoredInfectious Disease & HIV
2020
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
H. Jullien · Reviews in Antiviral Therapy & Infectious Diseases
Infectious Disease & HIV
2020
Disease Severity Impact on Long-Term Virologic Response to Ibalizumab In Expanded Access Protocol (Tmb-311)
P. Kumar · Open Forum Infectious Diseases
Infectious Disease & HIVTrial Methodology & Evidence
2020
Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma
Vladimír Tancoš · Pathology
RespiratoryOncology
2020
Ten tips for promoting your research
Timothy C. Hardman · Cardiovascular Endocrinology & Metabolism
Cardiovascular & HypertensionClinical Pharmacology & PK
2020
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges
S. Khan · Frontiers in Pharmacology
Niche authoredClinical Pharmacology & PK
2020
Vector Copy Distribution at a Single-Cell Level Enhances Analytical Characterization of Gene-Modified Cell Therapies
I. Santeramo · Molecular Therapy Methods & Clinical Development
Other
2019
Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus
L. Rodriguez-Mañas · Journal of Cachexia, Sarcopenia and Muscle
Diabetes & MetabolicAgeing & Frailty
2019
European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development—Be Prepared
Tim Hardman · Frontiers in Pharmacology
Niche authoredClinical Pharmacology & PK
2019
Evaluation of an increased strut porosity silicate-substituted calcium phosphate, SiCaP EP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open-label study
C. Bolger · European Spine Journal
Other
2019
Increasing the incidence of drain-free day-case mastectomies with the use of a fibrin tissue sealant; data from a single surgical center in the United Kingdom
C. Harrison · The Breast Journal
Other
2019
Lumbar interbody fusion rates with 3D-printed lamellar titanium cages using a silicate-substituted calcium phosphate bone graft
M. Mokawem · Journal of Clinical Neuroscience
Neurology & Psychiatry
2019
The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum
Kerstin Breithaupt-Grögler · Frontiers in Pharmacology
Niche authoredClinical Pharmacology & PKTrial Methodology & Evidence
2018
A Prospective, Randomized, Multicenter Study Comparing Silicated Calcium Phosphate versus BMP-2 Synthetic Bone Graft in Posterolateral Instrumented Lumbar Fusion for Degenerative Spinal Disorders
M. Coughlan · Spine
Other
2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
Catherine E. Hanratty · Trials
Niche authoredRespiratoryTrial Methodology & Evidence
2018
EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management
L. Van Bortel · Frontiers in Pharmacology
Niche authoredClinical Pharmacology & PK
2018
Healthy Aging
— · Medical Research Archives
Infectious Disease & HIVAgeing & Frailty
2018
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development
Susan Reijntjes · Frontiers in Pharmacology
Niche authoredClinical Pharmacology & PK
2017
Constipation in older people: A consensus statement
A. Emmanuel · International Journal of Clinical Practice
Ageing & Frailty
2017
Integration of ICH E4 cardiac safety in first time in man and other Phase I healthy volunteer studies
— · (Book chapter)
Cardiovascular & HypertensionClinical Pharmacology & PK
2017
Ready! Aim! Fire! targeting the right medical science journal
Timothy C. Hardman · Cardiovascular Endocrinology
Niche authoredCardiovascular & Hypertension
2017
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
B. C. Fellström · The Lancet
Other
2016
EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study
M. S. Berlin · British Journal of Ophthalmology
Cardiovascular & Hypertension
2016
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial
R. Eastell · Osteoporosis International
Clinical Pharmacology & PKMusculoskeletal & PainWomen's & Reproductive Health
2016
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Liam G. Heaney · Thorax
Niche authoredRespiratory
2016
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
M. Zeitlinger · Journal of Antimicrobial Chemotherapy
RespiratoryInfectious Disease & HIVOncology
2015
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus
E. Lawitz · Journal of Viral Hepatitis
Infectious Disease & HIVClinical Pharmacology & PKGastroenterology
2015
Assessment of SiCaP-30 in a Rabbit Posterolateral Fusion Model with Concurrent Chemotherapy
J. D. Smucker · Iowa Orthopaedic Journal
Oncology
2015
Bariatric surgery in obese older people
Susan J. Reijntjes · Cardiovascular Endocrinology
Niche authoredCardiovascular & HypertensionDiabetes & MetabolicAgeing & Frailty
2015
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey
C. Vidall · Supportive Care in Cancer
Oncology
2015
In Search of 'Omics'-Based Biomarkers to Predict Risk of Frailty and Its Consequences in Older Individuals: The FRAILOMIC Initiative
J. D. Erusalimsky · Gerontology
Niche authoredAgeing & Frailty
2015
Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects
X. Chen · Pharmacotherapy
Clinical Pharmacology & PK
2015
Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections
C. M. Rubino · Antimicrobial Agents and Chemotherapy
Infectious Disease & HIVOncologyClinical Pharmacology & PK
2015
Prostacyclin Synthase: Upregulation during Renal Development and in Glomerular Disease as well as Its Constitutive Expression in Cultured Human Mesangial Cells
T. Klein · Mediators of Inflammation
Renal & UrologyImmunology & Allergy
2015
Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers
F. Suto · Clinical Therapeutics
Clinical Pharmacology & PK
2015
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
J. M. Molina · The Lancet
Infectious Disease & HIVGastroenterology
2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial
S. Pianko · Annals of Internal Medicine
Infectious Disease & HIVGastroenterology
2015
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial
G. T. Everson · Annals of Internal Medicine
Infectious Disease & HIVGastroenterology
2014
A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects
H. Liu · Clinical Pharmacology in Drug Development
Clinical Pharmacology & PK
2014
An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes—the MID-Frail study: study protocol for a randomised controlled trial
Leocadio Rodríguez-Mañas · Trials
Niche authoredDiabetes & MetabolicAgeing & FrailtyTrial Methodology & Evidence
2014
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study
R. Eastell · Journal of Bone and Mineral Research
Musculoskeletal & PainWomen's & Reproductive Health
2014
Sarcoidosis: the links between epidemiology and aetiology
Simon Dubrey · Postgraduate Medical Journal
Niche authoredOther
2013
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma
N. G. Snowise · Current Medical Research and Opinion
Respiratory
2013
Directed osteogenic differentiation of human mesenchymal stem/precursor cells on silicate substituted calcium phosphate
K. Cameron · Journal of Biomedical Materials Research Part A
Musculoskeletal & Pain
2013
Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
R. M. Follows · Respiratory Research
RespiratoryClinical Pharmacology & PK
2013
Eight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and women
H. L. Lopez · Journal of the International Society of Sports Nutrition
Women's & Reproductive Health
2013
New therapies in the management of type 2 diabetes mellitus
T. C. Hardman · British Journal of Hospital Medicine
Niche authoredDiabetes & Metabolic
2013
New therapies to reduce low-density lipoprotein cholesterol
Anthony S. Wierzbicki · Current Opinion in Cardiology
Niche authoredCardiovascular & Hypertension
2013
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection
E. Lawitz · Antimicrobial Agents and Chemotherapy
Infectious Disease & HIVOncologyClinical Pharmacology & PK
2013
Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects
J. Denning · Antimicrobial Agents and Chemotherapy
Infectious Disease & HIVOncologyClinical Pharmacology & PK
2013
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections
W. T. Prince · Antimicrobial Agents and Chemotherapy
Infectious Disease & HIVOncologyDermatology
2013
The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study
Z. Zhang · Parkinsonism & Related Disorders
Neurology & Psychiatry
2012
Cardiovascular medication in women and urinary continence
S. Dubrey · Geriatric Medicine
Niche authoredCardiovascular & HypertensionAgeing & FrailtyRenal & Urology
2012
Drugs in development for the management of dyslipidaemia
A. S. Wierzbicki · Future Prescriber
Niche authoredCardiovascular & Hypertension
2012
Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination
A. Allen · Clinical Therapeutics
Clinical Pharmacology & PKRenal & UrologyGastroenterology
2012
Inhibition of pro-protein convertase subtilisin kexin 9 (PCSK-9) as a treatment for hyperlipidaemia
Anthony S. Wierzbicki · Expert Opinion on Investigational Drugs
Niche authoredCardiovascular & Hypertension
2012
Kerasal Nail Clinical Studies Demonstrate Early Visible Improvements in Nails Damaged by Onychomycosis
J. Faergemann · Podiatry Management
Other
2012
Midodrine: use and current status in the treatment of hypotension
J. F. Doyle · British Journal of Cardiology
Niche authoredCardiovascular & Hypertension
2012
New lipid-lowering drugs: an update
A. S. Wierzbicki · International Journal of Clinical Practice
Niche authoredCardiovascular & Hypertension
2012
Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers
A. Berges · Clinical Pharmacology in Drug Development
Neurology & PsychiatryClinical Pharmacology & PKMusculoskeletal & Pain
2012
Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research
B. Hocher · Kidney and Blood Pressure Research
Cardiovascular & HypertensionRenal & Urology
2012
Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study
L. Emtestam · Mycoses
Other
2011
Choosing the right Omega-3 supplement: Natural Triglyceride Omega-3 versus Synthetic Ethyl Ester
H. L. Lopez · Thera Health
Other
2011
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes
T. C. Hardman · Diabetes Therapy
Niche authoredDiabetes & Metabolic
2011
Early and Visible Improvements after Application of K101 in the Appearance of Nails Discoloured and Deformed by Onychomycosis
J. Faergemann · Journal of Cosmetics, Dermatological Sciences and Applications
Dermatology
2011
Effects of serum protein on ionic exchange between culture medium and microporous hydroxyapatite and silicate-substituted hydroxyapatite
K. Guth · Journal of Materials Science: Materials in Medicine
Other
2011
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study
S. Esser · European Journal of Medical Research
Infectious Disease & HIVClinical Pharmacology & PKTrial Methodology & Evidence
2011
Establishing bioequivalence for inhaled drugs; weighing the evidence
P. T. Daley-Yates · Expert Opinion on Drug Delivery
Clinical Pharmacology & PK
2011
Increasing strut porosity in silicate-substituted calcium-phosphate bone graft substitutes enhances osteogenesis
C. R. Campion · Journal of Biomedical Materials Research Part B
Musculoskeletal & Pain
2011
Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects
N. Lister · Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2011
Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double-blind, randomised, placebo-controlled studies
L. Emtestam · Mycoses
Dermatology
2010
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia
N. Valecha · PLoS One
Infectious Disease & HIV
2010
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis
J. Jenkins · European Journal of Clinical Pharmacology
Cardiovascular & HypertensionClinical Pharmacology & PK
2010
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects
A. Sarashina · Clinical Therapeutics
Diabetes & Metabolic
2010
Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'
Timothy C. Hardman · Current Pharmaceutical Design
Diabetes & Metabolic
2010
Surface Physiochemistry Affects Protein Adsorption to Stoichiometric and Silicate-Substituted Microporous Hydroxyapatites
K. Guth · Advanced Engineering Materials
Other
2010
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
D. Schuppan · Liver International
Infectious Disease & HIVClinical Pharmacology & PKGastroenterology
2009
Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models
L. Thomas · Journal of Pharmacology and Experimental Therapeutics
Diabetes & MetabolicClinical Pharmacology & PK
2009
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
H. Fuchs · Journal of Pharmacy and Pharmacology
Clinical Pharmacology & PK
2009
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies
D. D. Williams · Clinical Therapeutics
Clinical Pharmacology & PK
2009
Future challenges for microsomal transport protein inhibitors
Anthony S. Wierzbicki · Current Vascular Pharmacology
Cardiovascular & HypertensionClinical Pharmacology & PK
2009
Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes
J. Rungby · Expert Opinion on Investigational Drugs
Diabetes & Metabolic
2009
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks
F. Pulido · HIV Clinical Trials
Infectious Disease & HIV
2009
Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products
P. T. Daley-Yates · Clinical Therapeutics
RespiratoryClinical Pharmacology & PK
2008
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
L. Thomas · Journal of Pharmacology and Experimental Therapeutics
Clinical Pharmacology & PK
2008
HIV lipodystrophy and its metabolic consequences: implications for clinical practice
Anthony S. Wierzbicki · Current Medical Research and Opinion
Niche authoredInfectious Disease & HIVDiabetes & Metabolic
2008
HLA-B*5701 screening for hypersensitivity to abacavir
S. Mallal · New England Journal of Medicine
Other
2008
Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects
R. Dixon · British Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2008
Review: Clinical aspects of the management of HIV lipodystrophy
Anthony S. Wierzbicki · British Journal of Diabetes & Vascular Disease
Niche authoredCardiovascular & HypertensionInfectious Disease & HIVDiabetes & Metabolic
2008
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
S. Hüttner · Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2007
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
P. Flood-Page · American Journal of Respiratory and Critical Care Medicine
Respiratory
2007
Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor
M. J. Gunthorpe · Journal of Pharmacology and Experimental Therapeutics
Clinical Pharmacology & PK
2007
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
J. G. McHutchison · New England Journal of Medicine
Cardiovascular & HypertensionInfectious Disease & HIVGastroenterology
2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005
B. Hoen · Clinical Infectious Diseases
Infectious Disease & HIV
2006
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison
F. Smithuis · The Lancet
Infectious Disease & HIV
2006
Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone
F. C. Allen-Ramey · Current Medical Research and Opinion
Respiratory
2005
A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo
I. Hindmarch · Sleep
Neurology & PsychiatryClinical Pharmacology & PK
2005
A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers
I. Hindmarch · Psychopharmacology
Neurology & PsychiatryClinical Pharmacology & PK
2005
Characterization of the metabolites of alosetron in experimental animals and human
I. M. Ismail · Xenobiotica
Other
2005
Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects
R. Kempsford · Respiratory Medicine
RespiratoryClinical Pharmacology & PK
2005
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
S. Kinloch-de Loes · Journal of Infectious Diseases
Infectious Disease & HIVImmunology & Allergy
2005
Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years
P. McEwan · Current Medical Research and Opinion
Renal & Urology
2005
Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus
J. R. Cockcroft · American Journal of Hypertension
Cardiovascular & HypertensionDiabetes & Metabolic
2005
The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications
C. J. Currie · Diabetes Research and Clinical Practice
Cardiovascular & HypertensionDiabetes & Metabolic
2004
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients
R. Wood · Clinical Infectious Diseases
Infectious Disease & HIVClinical Pharmacology & PK
2004
A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
A. H. Barnett · Diabetes, Obesity and Metabolism
Diabetes & MetabolicClinical Pharmacology & PK
2004
Brief but efficient: acute HIV infection and the sexual transmission of HIV
C. D. Pilcher · Journal of Infectious Diseases
Infectious Disease & HIV
2004
Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death
C. J. Currie · Diabetes Research and Clinical Practice
Diabetes & Metabolic
2004
Evaluating the performance of the Framingham risk equations in a population with diabetes
P. McEwan · Diabetic Medicine
Diabetes & Metabolic
2004
Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service
C. J. Currie · Transfusion Medicine
Other
2004
GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks
S. MacManus · AIDS
Infectious Disease & HIV
2004
Safety of AT-1015, a novel 5-HT2A antagonist, in combination with high-dose aspirin: an open-label study
D. Anderson · International Journal of Clinical Pharmacology and Therapeutics
Clinical Pharmacology & PK
2004
Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate
M. Evans · Diabetes, Obesity and Metabolism
Cardiovascular & HypertensionDiabetes & MetabolicClinical Pharmacology & PK
2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
J. C. Gathe Jr · AIDS
Infectious Disease & HIV
2004
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients
A. Rodriguez-French · Journal of Acquired Immune Deficiency Syndromes
Infectious Disease & HIVImmunology & Allergy
2004
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)
A. Vibhagool · Current Medical Research and Opinion
Infectious Disease & HIV
2003
Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease
S. D. Singh · British Journal of Clinical Pharmacology
RespiratoryClinical Pharmacology & PK
2003
The effect of nateglinide taken with food on gastric emptying rates in healthy subjects
D. Anderson · Clinical Therapeutics
Other
2002
A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers
D. M. Anderson · International Journal of Clinical Pharmacology and Therapeutics
Clinical Pharmacology & PK
2002
A patient with HIV-1 superinfection
S. Jost · New England Journal of Medicine
Infectious Disease & HIV
2002
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection
K. Loré · AIDS
Infectious Disease & HIV
2002
Correction for the adverse influence of sodium-potassium cotransport on apparent sodium-lithium countertransport activity in human erythrocytes
Timothy C. Hardman · Journal of Pharmacological and Toxicological Methods
Niche authoredClinical Pharmacology & PK
2002
HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial
D. A. Jabs · AIDS
Infectious Disease & HIV
2002
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection
J. Andersson · Journal of Infectious Diseases
Infectious Disease & HIVImmunology & Allergy
2002
No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers
D. M. Anderson · Journal of Clinical Pharmacology
Diabetes & MetabolicClinical Pharmacology & PK
2002
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection
R. Tilling · AIDS
Infectious Disease & HIV
2002
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers
Christine Falcoz · Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2002
The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter
Anthony S. Wierzbicki · American Journal of Hypertension
Niche authoredCardiovascular & Hypertension
2002
The cardiological complications associated with HIV infection and acquired immune deficiency syndrome (AIDS)
T. C. Hardman · British Journal of Cardiology
Niche authoredCardiovascular & HypertensionInfectious Disease & HIVImmunology & Allergy
2001
Apolipoprotein E gene polymorphism and sodium-lithium countertransport activity
T. Hardman · Metabolism
Niche authoredClinical Pharmacology & PK
2001
Changes in referral patterns to cardiac out-patient clinics with ambulatory ECG monitoring in general practice
P. Standing · British Journal of Cardiology
Cardiovascular & Hypertension
2001
Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects
S. D. Luzio · Journal of Clinical Endocrinology & Metabolism
Diabetes & MetabolicClinical Pharmacology & PK
2001
Erythrocyte sodium-lithium countertransport in African American women
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & HypertensionWomen's & Reproductive Health
2001
Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor
K. H. Moore · European Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2001
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers
K. H. Moore · Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2001
Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia
A. S. Wierzbicki · American Journal of Hypertension
Niche authoredCardiovascular & Hypertension
2001
Sodium-lithium countertransport activity is linked to chromosome 5 in baboons
T. C. Hardman · Hypertension
Niche authoredCardiovascular & Hypertension
2001
Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study
L. E. Goh · HIV Clinical Trials
Infectious Disease & HIVTrial Methodology & Evidence
2001
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers
L. M. Cass · Journal of Clinical Pharmacology
Clinical Pharmacology & PK
2001
The current status of antihypertensive treatments: into the new millennium
T. C. Hardman · Expert Opinion on Pharmacotherapy
Niche authoredCardiovascular & Hypertension
2000
Brain and CSF entry of the novel non-nucleoside reverse transcriptase inhibitor, GW420867X
S. Thomas · NeuroReport
Neurology & Psychiatry
2000
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
S. A. Mallal · AIDS
Infectious Disease & HIV
2000
Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter
A. S. Wierzbicki · Journal of Human Hypertension
Niche authoredCardiovascular & Hypertension
2000
In bed with the enemy
S. Purdon · Clinical Research Focus
Other
2000
Natriuretic peptides and heart failure: diagnosis, prognosis and treatment
S. W. Dubrey · British Journal of Cardiology
Niche authoredCardiovascular & Hypertension
2000
The QUEST trial, a paradigm of HIV collaborative research
L. E. Goh · Nature Medicine
Infectious Disease & HIV
1999
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR)
G. J. Dore · Journal of Infectious Diseases
Infectious Disease & HIVGastroenterologyImmunology & Allergy
1999
Enhanced activity of the sodium lithium countertransporter in patients with cardiac syndrome X: a potential link between cardiac syndrome X and metabolic syndrome X
Timothy C. Hardman · Journal of the American College of Cardiology
Niche authoredCardiovascular & HypertensionDiabetes & Metabolic
1999
Erythrocyte Na+/Li+ countertransport and Na+/K+ -2Cl- co-transport in essential hypertension
T. Hardman · Clinical Science
Niche authoredCardiovascular & Hypertension
1999
Na,Li-countertransport and ethnicity
T. C. Hardman · American Journal of Hypertension
Niche authoredCardiovascular & Hypertension
1999
Transport of phytanic acid on lipoproteins in Refsum disease
A. S. Wierzbicki · Journal of Inherited Metabolic Disease
Niche authoredDiabetes & Metabolic
1999
Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & HypertensionRenal & Urology
1998
Cation transport in Bartter's syndrome
Timothy C. Hardman · Journal of Hypertension
Niche authoredCardiovascular & Hypertension
1998
Characterization of the Erythrocyte Sodium-Lithium Countertransporter: Limitations and Assumptions of Traditional and Kinetic Methodologies
Timothy C. Hardman · Journal of Membrane Biology
Niche authoredTrial Methodology & Evidence
1998
Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter
Timothy C. Hardman · European Journal of Clinical Investigation
Niche authoredOther
1998
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in black normotensive subjects compared with three other ethnic groups
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & Hypertension
1996
Angiotensin-converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in hypertension
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & Hypertension
1996
Controversies surrounding erythrocyte sodium-lithium countertransport
T. C. Hardman · Journal of Hypertension
Niche authoredCardiovascular & Hypertension
1996
Dietary fat and risk of coronary heart disease in men
T. C. Hardman · BMJ
Niche authoredCardiovascular & Hypertension
1996
Erythrocyte sodium-lithium countertransport activity in non-nephropathic diabetic twins
T. C. Hardman · Diabetes Care
Niche authoredDiabetes & Metabolic
1996
Kinetic behavior of the erythrocyte sodium-lithium countertransporter in nonnephropathic diabetic twins
T. C. Hardman · Metabolism
Niche authoredDiabetes & MetabolicClinical Pharmacology & PK
1996
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery disease
T. C. Hardman · American Journal of Hypertension
Niche authoredCardiovascular & Hypertension
1995
Ethnic origin and hypertension-associated alterations in sodium-lithium countertransport kinetics
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & Hypertension
1995
Insulin - the cardiologist's viewpoint
S. W. Dubrey · British Journal of Cardiology
Niche authoredCardiovascular & HypertensionDiabetes & Metabolic
1995
Relation of sodium-lithium countertransport activity to markers of cardiovascular risk in normotensive subjects
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & Hypertension
1994
Exercise electrocardiography and aortic Doppler velocimetry in asymptomatic identical twins discordant for type 1 (insulin dependent) diabetes
S. Dubrey · British Heart Journal
Niche authoredCardiovascular & HypertensionDiabetes & Metabolic
1994
Lack of acute effects of a standardised fat meal or exercise on erythrocyte sodium-lithium countertransport activity
T. C. Hardman · Journal of Human Hypertension
Niche authoredCardiovascular & Hypertension
1992
Erythrocyte sodium-lithium countertransport and blood pressure in identical twin pairs discordant for insulin dependent diabetes
T. C. Hardman · BMJ
Niche authoredCardiovascular & HypertensionDiabetes & Metabolic